Under the Paperwork Reduction Act of 1995, no persons are required to re-

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10549633		
Filing Date		2006-02-10		
First Named Inventor Kevin		Drage		
Art Unit		3683		
Examiner Name Bradi		ey T. King		
Attorney Docket Number		043210-1821-00		

				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	ber Sind Issue Date Name of Patentee or Applicant R		Releva	Columns,Lines where nt Passages or Relev s Appear			
	1	6336531		2002-01-08	Chou				
	2	6357557		2002-03-19	Di Ponio				
If you wisi	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add	
			U.S.P	ATENT APPL	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Pal of cited Door	tentee or Applicant ument	Releva	Columns,Lines when nt Passages or Rele s Appear	
If you wisi	h to a	dd additional U.S. Publ	ished Ap	plication citation			d button	Add	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	200136836	wo		2000-11-15	Newtech Brake Corporation Inc.			С
If you wis	h to a	dd additional Foreign F	atent Do	cument citation	n information p	lease click the Add	button	Add	_
				I-PATENT LIT				Remove	

Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	Ţ5
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

"EXAMINET: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 See Krid Codes of UBPTO Patient Documents all princt USETIO_GODY or MPEP 801.84. "Entire office that issued the document, by the involved code (NIPO Detected 07.75). "The Apparets patient Concerns, the robuston of the page of the improve must previous the sense in united of the pages of the improve must previous the sense in united of the pages of the improve must previous the sense in united of the pages of the improve must previous the sense in united of the pages of the improve must previous the sense in the pages of the improve must previous the sense in the pages of the improve must previous the sense in the pages of the improve must previous the sense in the pages of the improve must previous the sense in the pages of the improvement of the intervent of the improvement of the improv

English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10549633	
Filing Date		2006-02-10	
First Named Inventor	Kevin Drage		
Art Unit		3683	
Examiner Name	Bradie	ey T. King	
Attorney Docket Number		043210-1821-00	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information displacate statement. Con 27 CED 1 07(a)/1)

OR

	That no item of information contained in the information disclosure statement was cited in a communication from a
	foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
	after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
_	any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
	statement, See 37 CFR 1.97(e)(2).

1	See	attached	certification	statement.

٦	Fee set forth in 37	7 CFR 1.17 (p)	has been submitted herewith.

_

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/glen a. weitzer/	Date (YYYY-MM-DD)	2007-05-15
Name/Print	Glen A Weitzer	Registration Number	48337

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.